Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00854126 |
This is an open-label, multicenter, Phase I study to evaluate the safety, tolerability, and pharmacokinetics of escalating oral doses of GDC-0980 administered to patients with incurable, locally advanced or metastatic solid malignancy or NHL that has progressed or failed to respond to at least one prior regimen or for which there is no standard therapy.
Condition | Intervention | Phase |
---|---|---|
Non-Hodgkin's Lymphoma Solid Cancers |
Drug: GDC-0980 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label, Uncontrolled, Single Group Assignment |
Official Title: | An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0980 Administered Once Weekly in Patients With Refractory Solid Tumors or Non-Hodgkin's Lymphoma |
Estimated Enrollment: | 63 |
Study Start Date: | April 2009 |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: GDC-0980
Escalating repeating dose
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Genentech, Inc. ( Clinical Trials Posting Group ) |
Study ID Numbers: | PIM4605g |
Study First Received: | February 27, 2009 |
Last Updated: | February 27, 2009 |
ClinicalTrials.gov Identifier: | NCT00854126 History of Changes |
Health Authority: | United States: Food and Drug Administration |
NHL Solid Tumors Carcinogenic Tumors |
Lymphoma, Small Cleaved-cell, Diffuse Lymphatic Diseases Immunoproliferative Disorders |
Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma |
Lymphatic Diseases Neoplasms Immunoproliferative Disorders Neoplasms by Histologic Type |
Immune System Diseases Lymphoproliferative Disorders Lymphoma, Non-Hodgkin Lymphoma |